SCHEMBL12257590

SCHEMBL12257590

OC[C@H]1S[C@@H](c2cccc(Cc3nc4ccccc4s3)c2)[C@H](O)[C@@H](O)[C@@H]1O

nearest known ligand 0.67

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC5A2 P31639 15/20 0.67
SLC5A1 P13866 7/20 0.52
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
POLB P06746 1/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
HTT P42858 1/20 0.41
KMT2A Q03164 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
UBE2T Q9NPD8 1/20 0.38
ASIC3 Q9UHC3 1/20 0.38
PTGS1 P23219 1/20 0.37
PTGS2 P35354 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12336661 0.89 SLC5A2 (0.57) SLC5A2SLC5A1KDM4EMEN1ALDH1A1
SCHEMBL12426013 0.81 SLC5A2 (1.00) SLC5A2
SCHEMBL12257577 0.80 SLC5A2 (0.67) SLC5A2SLC5A1
SCHEMBL17480497 0.76 SLC5A2 (0.70) SLC5A2KDM4EMEN1ALDH1A1LMNA
SCHEMBL12257550 0.74 SLC5A2 (0.72) SLC5A2SLC5A1
SCHEMBL12257479 0.74 SLC5A2 (0.47) SLC5A2SLC5A1KDM4EMEN1ALDH1A1
SCHEMBL12776486 0.74 SLC5A2 (0.47) SLC5A2KDM4EMEN1ALDH1A1LMNA
SCHEMBL12257584 0.73 SLC5A2 (0.52) SLC5A2SLC5A1KDM4EMAPT
SCHEMBL12257586 0.73 SLC5A2 (0.54) SLC5A2SLC5A1
SCHEMBL30306726 0.73 SLC5A2 (0.51) SLC5A2KDM4EMEN1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8017792-B2 1-thio-D-glucitol derivatives TAISHO PHARMACEUTICAL CO., LTD. (JP) 2011-09-13 US disclosed
US-20110098469-A1 1-THIO-D-GLUCITOL DERIVATIVES TAISHO PHARMACEUTICAL CO., LTD. (JP) 2011-04-28 US disclosed
US-7910619-B2 e.g. 2,3,4,6-tetra-O-benzyl-5-thio-D-glucono-1,5-lactone3,4-Dihydro-2H-pyran; inhibit the activity of sodium-dependent glucose cotransporter 2 (SGLT2) concerned with glucose reabsorption in the kidney; antidiabetic agent; diabetes-related disease, or diabetic complication TAISHO PHARMACEUTICAL CO., LTD. (JP) 2011-03-22 US disclosed
US-20080132563-A1 1-Thio-D-Glucitol Derivatives TAISHO PHARMACEUTICAL CO., LTD. (JP) 2008-06-05 US disclosed
EP-1845095-A1 1-THIO-D-GLUCITOL DERIVATIVES TAISHO PHARMACEUTICAL CO., LTD (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098469-A1 1-THIO-D-GLUCITOL DERIVATIVES SLC5A1, SLC5A2, SLC5A11 SLC5A2 2/4885SLC5A1 1/4885KDM4E 2838/4885
US-20080132563-A1 1-Thio-D-Glucitol Derivatives SLC5A1, SLC5A2, SLC5A11 SLC5A2 2/4885SLC5A1 1/4885KDM4E 2838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.